Simplifying ChIP from Primary Cells and Clinical Samples for Epigenetic Applications

This event offers an overview of how live-cell analysis enables real-time analysis for the full workflow of the cells. Start at the beginning and learn more about the cell health, growth and morphology of your cells in culture. From there, gain a better understanding of the efficiency of transfection and how the consistency of cell plating as well pre-treatments can affect your cells during manipulation, all the way to the final kinetic assay itself. You’ll receive in-depth content designed to give you the tools and insights of live-cell analysis to make data driven decisions.

This webinar will compare and contrast three (3) meaningful Life Cycle Approaches - Predictive, Iterative and Agile. In doing so, it will look at the implications of the ‘Knowledge Environment’ on the life cycle approaches and attempt to equip project management practitioners with the knowledge necessary to adopt a leadership style that allows them to thrive in this environment by working with the sponsoring organization in selecting the right approach for managing the project at hand based on its attributes.

Interest in 3D cell culture has grown exponentially in recent years, partially due to 3D cultures helping to overcome the challenges of using animal models and inadequacy of 2D cultures. Challenges are still present because of the physical nature of 3D cultures, especially when using confocal microscopy for visualization as a result of limited light penetration through 3D structures. To overcome these limitations, Nano3D Biosciences and MD Anderson together have developed methods and protocols using magnetic 3D bioprinting techniques to successfully overcome such challenges. The results have helped to identify novel approaches to study biology using 3D cell culture and automated confocal imaging of spheroids.

The management of cancer patients in clinical practice is undergoing a revolution due to the introduction of effective immunotherapy. Several different strategies currently rely on harnessing the immune system to fight tumors, leading to unprecedented therapeutic success. However, immunotherapy has also created the need to revisit the assessment of treatment benefit, possibly because its mechanism of action leads to effects on short- and long-term outcomes in a manner that differs from those of other modalities. For example, clinical trials of immune checkpoint inhibitors have disclosed novel issues related to the assessment of objective responses and have reinstated overall survival as a reliable primary endpoint, often to the detriment of progression-free survival (PFS). Moreover, pseudoprogression has become an issue in some tumor types, and the duration of responses has emerged as a relevant endpoint. In parallel, the limitations of current statistical methods of survival analysis that are based on the proportional-hazards assumption have become more apparent, and novel methods have been proposed.